SCHEMBL1335522

SCHEMBL1335522

COc1cccc(-c2cc(F)c(N)c(F)c2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.55
CYP1A1 P04798 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2E1 P05181 1/20 0.55
CYP2C8 P10632 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2A6 P11509 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP4B1 P13584 1/20 0.55
CYP2B6 P20813 1/20 0.55
CYP3A5 P20815 1/20 0.55
CYP2A7 P20853 1/20 0.55
CYP3A7 P24462 1/20 0.55
CYP2F1 P24903 1/20 0.55
CYP2C18 P33260 1/20 0.55
CYP2C19 P33261 1/20 0.55
CYP2J2 P51589 1/20 0.55
CYP4F2 P78329 1/20 0.55
CYP4F8 P98187 1/20 0.55
CYP4A11 Q02928 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1650160 0.98 MAOB (0.54) CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8
SCHEMBL29868542 0.88 DHODH (0.51) CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8
SCHEMBL1337887 0.84 MAOB (0.55) CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8
SCHEMBL12777827 0.82 CYP1A1 (0.55) CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8
SCHEMBL1650912 0.82 ENPP2 (0.55) CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8
SCHEMBL1336946 0.81 RXRA (0.51) CYP1A2CYP2C19MAP4K4DHODHBACE1
SCHEMBL1337634 0.81 TP53 (0.54) CYP3A4KDM4EMAP4K4DHODH
SCHEMBL3731784 0.81 KDM1A (0.53) CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8
SCHEMBL196765 0.80 CYP3A4 (0.73) CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8
SCHEMBL29489425 0.80 CYP3A4 (0.73) CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488497-B1 PROCESS FOR MANUFACTURING 2-[(3,5-DIFLUORO-3'-METHOXY-1,1'-BIPHENYL-4-YL)AMINO]NICOTINIC ACID ALMIRALL SA (ES) 2014-03-12 EP claimed
US-8598363-B2 Process for manufacturing 2-[(3,5-difluoro-3′-methoxy-1,1′biphenyl-4-yl)amino]nicotinic acid ALMIRALL, S.A. (ES) 2013-12-03 US claimed
US-20120245359-A1 PROCESS FOR MANUFACTURING 2-[(3,5-DIFLUORO-3'-METHOXY-1,1'-BIPHENYL-4 YL)AMINO]NICOTINIC ACID ALMIRALL, S.A. (ES) 2012-09-27 US claimed
EP-2488497-A1 PROCESS FOR MANUFACTURING 2-[(3,5-DIFLUORO-3'-METHOXY-1,1'-BIPHENYL-4-YL)AMINO]NICOTINIC ACID Almirall S.A. (ES) 2012-08-22 EP claimed
EP-2314577-A1 Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid Almirall, S.A. (ES) 2011-04-27 EP claimed
WO-2011045059-A1 PROCESS FOR MANUFACTURING 2-[(3,5-DIFLUORO-3'-METHOXY-1,1'-BIPHENYL-4-YL)AMINO]NICOTINIC ACID ALMIRALL, S.A. (ES) 2011-04-21 WO claimed
US-20260130879-A1 VIDOFLUDIMUS AND RELATED STRUCTURES ACTING AS NURR1 AGONISTS IMMUNIC AG (DE) 2026-05-14 US disclosed
US-20240335405-A1 VIDOFLUDIMUS AND RELATED STRUCTURES ACTING AS NURR1 AGONISTS IMMUNIC AG (DE) 2024-10-10 US disclosed
WO-2023118576-A1 DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE IMMUNIC AG (DE) 2023-06-29 WO disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
CN-102574800-B Method for producing 2- [ (3, 5-difluoro-3 '-methoxy-1, 1' -biphenyl-4-yl) amino ] nicotinic acid ALMIRALL SA 2014-09-17 CN disclosed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US disclosed
CN-103936668-A Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid ALMIRALL SA 2014-07-23 CN disclosed
EP-2314577-A1 Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid Almirall, S.A. (ES) 2011-04-27 EP disclosed
WO-2011045059-A1 PROCESS FOR MANUFACTURING 2-[(3,5-DIFLUORO-3'-METHOXY-1,1'-BIPHENYL-4-YL)AMINO]NICOTINIC ACID ALMIRALL, S.A. (ES) 2011-04-21 WO disclosed
WO-2011045059-A1 PROCESS FOR MANUFACTURING 2-[(3,5-DIFLUORO-3'-METHOXY-1,1'-BIPHENYL-4-YL)AMINO]NICOTINIC ACID ALMIRALL, S.A. (ES) 2011-04-21 WO disclosed
WO-2011045059-A1 PROCESS FOR MANUFACTURING 2-[(3,5-DIFLUORO-3'-METHOXY-1,1'-BIPHENYL-4-YL)AMINO]NICOTINIC ACID ALMIRALL, S.A. (ES) 2011-04-21 WO disclosed
US-20100074898-A1 AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS LABORATORIOS ALMIRALL, S.A. (ES) 2010-03-25 US disclosed
EP-2121614-A1 AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS Almirall, S.A. (ES) 2009-11-25 EP disclosed
WO-2008077639-A1 AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS LABORATORIOS ALMIRALL, S.A. (ES) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR CYP3A4 1738/4885CYP1A1 1640/4885CYP1A2 1449/4885
US-20260130879-A1 VIDOFLUDIMUS AND RELATED STRUCTURES ACTING AS NURR1 AGONISTS NR0B1, NR4A1, NR4A2 CYP3A4 1859/4885CYP1A1 1272/4885CYP1A2 1784/4885
US-20100074898-A1 AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS DHODH, NQO2, DAO CYP3A4 2249/4885CYP1A1 1233/4885CYP1A2 1156/4885
US-20120245359-A1 PROCESS FOR MANUFACTURING 2-[(3,5-DIFLUORO-3'-METHOXY-1,1'-BIPHENYL-4 YL)AMINO]NICOTINIC ACID GART, NAPRT, NNMT CYP3A4 270/4885CYP1A1 127/4885CYP1A2 494/4885
US-20240335405-A1 VIDOFLUDIMUS AND RELATED STRUCTURES ACTING AS NURR1 AGONISTS NR4A1, NR4A2, NR0B1 CYP3A4 2354/4885CYP1A1 1772/4885CYP1A2 2388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.